In trials, GLP-1 medications also reduce: Non-HDL cholesterol and triglycerides Systolic blood pressure (typically 36 mmHg) High-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation by as much as 47.7% in ATTAIN-1 [2] HbA1c in patients with type 2 diabetes or prediabetes Early and emerging evidence suggests benefits in other conditions too
We found that the opportunities arent just in changing the recipe
The synthetic version is studied for tissue healing, gut health, and anti-inflammatory balance
reuteri can significantly increase natural GLP-1 production
Peptides (TB-500, GHK-Cu, and Ipamorelin) target narrower recovery pathways, making direct comparisons useful for understanding the scope of each compound's preclinical evidence
Additionally, research shows a link between poor glutathione status and autoimmune Hashimotos hypothyroidism